Moving transperineal prostate biopsy into the clinic
Learning curve for technique is short, but capital expenditures are required.
What will be the next GOAT for bladder cancer?
"The future is bright for immunotherapy in bladder cancer," writes Michael S. Cookson, MD, MMHC.
What is the role of prostate-specific antigen screening in your practice?
"I use PSA testing to make sure patients with high-risk prostate cancer, specifically, and advanced prostate cancer, or even metastatic prostate cancer, don’t go undiagnosed," says 1 urologist.
The urologist in the world of precision medicine
"What exactly is precision medicine?...One of the original [LUGPA] board members put it very simply: cheaper, faster, and better," writes Raoul S. Concepcion, MD, FACS.
Urology Coding: Can N20.0 and N13.2 be billed on the same CPT line?
Payer edits referencing ICD-10-CM guidelines such as “Excludes 1” are on the rise.
Lawsuit alleges urethral injury following ED visit
Plaintiff claims defendant negligently failed to order urology consult.
8 steps to create your 2022 financial plan
Having a year-to-year strategy helps you achieve short- and long-term goals.
PARP inhibitor niraparib shows promise in mCRPC with DNA repair gene defects
“Such findings underscore the need for and importance of molecular testing to inform management along with continued research to establish treatment paradigms with appropriately targeted therapies for patients with prostate cancer,” the authors wrote.
6 steps to help you track ureteral stents
Think of the forgotten stent primarily as a patient safety issue, writes Robert A. Dowling, MD.
Gender disparities found in bladder cancer trials and real-world systemic therapy use
“We have to be more mindful and thoughtful about the fact that certain populations are underrepresented in clinical trials, and that’s likely due to a number of factors,” said co-author Padraic O’Malley, MD, MSc, FRCSC.
Why do patients prefer some OAB third-line therapies over others?
“Patients are overwhelmed by these choices often, and don't really understand the risks and benefits when they're first told about them,” said co-author Anjali Kapur, MD.
Midurethral sling opens up treatment of stress urinary incontinence to more patients
In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Howard Goldman, MD, discusses the development of the midurethral sling as a treatment for stress urinary incontinence.
Chemothermotherapy shows promise in non–muscle-invasive bladder cancer
In this interview, Brant A. Inman, MD, MS, FRCSC, discusses how investigational chemothermotherapy could mitigate some challenges presented by current NMIBC treatments.
Worldwide genetic testing rates are low for patients with prostate cancer
Cost was the most commonly reported barrier to genetic testing.
Researchers look to neoadjuvant setting to advance RCC paradigm
Naomi B. Haas, MD, discusses efforts to improve care in locally advanced renal cell carcinoma through research in the neoadjuvant setting.
Dr. Newmark provides updates on FDA-approved oral testosterone undecanoate
In a recent study presented at the 2021 SMSNA Fall Scientific Meeting, Jay Newmark, MD, MBA, and co-authors report promising findings on the first experiences of patients using JATENZO in the real world.
2 Clarke Drive Cranbury, NJ 08512